R&D
Ending trial-and-error: How psychedelics and precision medic...
The next phase of psychiatry must go toward treatments that are not only novel, but practical, personalised, and accessible.
News
Where others missed, AZ's IL-33 drug hits the mark in COPD
AZ's IL-33 inhibitor tozorakimab hits the mark in two late-stage COPD trials, raising the prospects of a class that has had some failures in the past.
News
Novartis snaps up food allergy firm Excellergy for $2bn
Novartis has signed its second M&A deal in the space of a week, pledging to pay up to $2 billion to acquire US food allergy drug developer Excellergy.
News
Wave's stock wavers on obesity drug data
Wave Life Sciences has said new clinical trial results with its non-incretin therapy for weight loss are positive – but investors don't seem to agree.
R&D
Regulatory setback or scientific signal? The case for human-...
Exploring a systemic challenge in translating biological promise into reliable human efficacy and safety.
Debates & Insights
News
Press Releases
Editor's Picks
Editor's Picks
